Is AstraZeneca PLC (AZN) A Good Stock To Buy Now?

AstraZeneca PLC has evolved from its origins successful the 19th-century chemicals manufacture into 1 of the world’s starring pharmaceutical companies, with roots tracing backmost to Nobel Industries and the enactment of Imperial Chemical Industries (ICI). The modern institution emerged aft the 1993 demerger of Zeneca from ICI and its consequent merger with Astra AB successful 1999, combining complementary strengths crossed therapeutic areas.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Today, AstraZeneca operates crossed oncology, uncommon diseases, and biopharmaceuticals, with oncology arsenic its crown jewel contributing astir 44% of revenue, supported by blockbuster drugs similar Tagrisso, Imfinzi, and Enhertu. The 2021 acquisition of Alexion strengthened its uncommon diseases segment, portion biopharmaceuticals stay a large contributor with products specified arsenic Farxiga.

The company’s translation nether CEO Pascal Soriot has been pivotal, peculiarly successful navigating the early-2010s patent cliff done accrued R&D concern and pipeline expansion. AstraZeneca present boasts astir 200 projects, including implicit 100 successful late-stage Phase 3 trials, reinforcing its competitory moat successful a high-barrier manufacture defined by agelong improvement cycles and regulatory complexity. Financially, beardown gross growth, a PEG ratio of astir 0.72, and a 45% EPS CAGR from 2022–2025 suggest the marketplace whitethorn inactive beryllium underappreciating its net trajectory.

Geographically, the U.S. is its largest market, and caller argumentation risks person been mitigated done a $50 cardinal concern committedness securing tariff exemptions and favorable pricing arrangements. Combined with demographic tailwinds specified arsenic aging populations and rising crab incidence, AstraZeneca is well-positioned for semipermanent growth. With ambitious targets of $80 cardinal successful gross by 2030, a beardown pipeline, and proven leadership, the institution presents a compelling lawsuit supported by some structural manufacture drivers and interior execution.

Previously, we covered a bullish thesis connected Pfizer Inc. (PFE) by Akim Guerreiro successful September 2024, which highlighted the company’s precocious dividend yield, post-COVID normalization impact, and betterment imaginable driven by its pipeline and strategical acquisitions. PFE’s banal terms has depreciated by astir 6.34% since our coverage. South Sea Investing shares a akin presumption but emphasizes connected AstraZeneca’s stronger pipeline extent and oncology leadership.